KRAS G12R mutation is linked to more favorable patient outcomes, with longer median overall survival and time to next treatment. The study involving 2,433 patients highlights the need for KRAS variant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback